Monoclonal antibody (mAb) development is increasingly moving toward high-concentration formulations to support subcutaneous delivery, improve patient convenience, and enable next-generation therapeutics. But as protein concentrations rise, ultrafiltration and diafiltration (UF/DF) processes face a new set of challenges.
Higher concentrations increase viscosity, narrow operating windows, and amplify the risks of fouling and aggregation. These effects are closely connected, making process performance and control more difficult to maintain using conventional approaches.
This webinar examines the three critical UF/DF challenges associated with high-concentration mAbs and the process strategies and modern tangential flow filtration (TFF) technologies being used to address them.
Download the webinar to discover:
- Why the shift to high-concentration mAbs is changing UF/DF requirements across development and manufacturing
- Why viscosity, fouling, and aggregation become critical challenges as mAb concentrations increase
- How modern, automated TFF platforms can help mitigate these challenges and support more robust, repeatable UF/DF processes
Monoclonal antibody (mAb) development is increasingly moving toward high-concentration formulations to support subcutaneous delivery, improve patient convenience, and enable next-generation therapeutics. But as protein concentrations rise, ultrafiltration and diafiltration (UF/DF) processes face a new set of challenges.
Higher concentrations increase viscosity, narrow operating windows, and amplify the risks of fouling and aggregation. These effects are closely connected, making process performance and control more difficult to maintain using conventional approaches.
This webinar examines the three critical UF/DF challenges associated with high-concentration mAbs and the process strategies and modern tangential flow filtration (TFF) technologies being used to address them.
Download the webinar to discover:
Why the shift to high-concentration mAbs is changing UF/DF requirements across development and manufacturing
Why viscosity, fouling, and aggregation become critical challenges as mAb concentrations increase
How modern, automated TFF platforms can help mitigate these challenges and support more robust, repeatable UF/DF processes
